Reed Benson - Co Diagnostics CFO, Secretary

CODX
 Stock
  

USD 2.78  0.11  3.81%   

  CFO
Mr. Reed L Benson serves as Chief Financial Officer, Secretary of the Company. He was Chief Financial Officer and Secretary from November 2014 to the present and a director from November 2014 to May 2017. Since September, 2008 to the present, in addition to the private practice of law, he is a founder and partner of Legends Capital Group, LLC, a privately held VC group that identifies investment opportunities in natural resources, bio tech and technology fields. From October 2004 to September 2008 he was employed as Chief Financial Officer, Secretary, and General Counsel and member of Board of Directors of Broadcast International, Inc., a publicly traded communications services company. From 2001 to October 2004, he was in the private practice of law where his practice focused on tax and business related matters. From July 1995 to January 2001 he was secretary and general counsel for Data Broadcasting Corporationrationration, a provider of market information to individual investors. Mr. Benson received his J.D. degree from the University of Utah School of Law in 1976 and a BS Degree in Accounting from the University of Utah in 1971. Mr. Benson became a Certified Public Accountant in 1974.
Age: 74  CFO Since 2017      
801 438 1036  https://www.codiagnostics.com

Reed Benson Latest Insider Activity

Tracking and analyzing the buying and selling activities of Reed Benson against Co Diagnostics stock is an integral part of due diligence when investing in Co Diagnostics. Reed Benson insider activity provides valuable insight into whether Co Diagnostics is net buyers or sellers over its current business cycle. Note, Co Diagnostics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Co Diagnostics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Co Diagnostics Management Efficiency

Co-Diagnostics has return on total asset (ROA) of 0.0467 % which means that it generated profit of $0.0467 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.129 %, meaning that it created $0.129 on every $100 dollars invested by stockholders. Co Diagnostics management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 418.82 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Co-Diagnostics has a current ratio of 16.61, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Co Diagnostics until it has trouble settling it off, either with new capital or with free cash flow. So, Co Diagnostics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Co-Diagnostics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Co Diagnostics to invest in growth at high rates of return. When we think about Co Diagnostics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 1 records

CFO Since

Laurence DebrouxHeineken Holding NV
2015
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection andor analysis of nucleic acid molecules in the United States and internationally. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Co Diagnostics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 101 people. Co-Diagnostics (CODX) is traded on NASDAQ Exchange in USA and employs 101 people. Co Diagnostics is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Co-Diagnostics Leadership Team

Elected by the shareholders, the Co Diagnostics' board of directors comprises two types of representatives: Co Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Co Diagnostics. The board's role is to monitor Co Diagnostics' management team and ensure that shareholders' interests are well served. Co Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Co Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Edward Borkowski, Independent Director
Andrew Benson, Head Relations
Richard Serbin, Independent Director
Edward Murphy, Independent Director
Brian CPA, CFO Sec
Frank Kiesner, Independent Director
Eugene Durenard, Independent Director
Mayuranki Almaula, VP Alliances
Dan CPA, VP Accounting
Reed Benson, CFO, Secretary
Cameron Gundry, Head LATAMEUR
Brent Satterfield, Chief Science Officer, Director
Dwight Egan, Chairman of the Board and Presidentident, CEO
Mark Poritz, Chief Officer

Co Diagnostics Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Co Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Co Diagnostics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Theme Ratings Now

   

Theme Ratings

Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Pair Trading with Co Diagnostics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Co Diagnostics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Co Diagnostics will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Co Diagnostics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Co Diagnostics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Co Diagnostics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Co-Diagnostics to buy it.
The correlation of Co Diagnostics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Co Diagnostics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Co-Diagnostics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Co Diagnostics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. Note that the Co-Diagnostics information on this page should be used as a complementary analysis to other Co Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Fund Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Complementary Tools for Co Diagnostics Stock analysis

When running Co-Diagnostics price analysis, check to measure Co Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Co Diagnostics is operating at the current time. Most of Co Diagnostics' value examination focuses on studying past and present price action to predict the probability of Co Diagnostics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Co Diagnostics' price. Additionally, you may evaluate how the addition of Co Diagnostics to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Is Co Diagnostics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Co Diagnostics. If investors know Co Diagnostics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Co Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
0.308
Market Capitalization
86 M
Quarterly Revenue Growth YOY
(0.83) 
Return On Assets
0.0467
Return On Equity
0.129
The market value of Co-Diagnostics is measured differently than its book value, which is the value of Co Diagnostics that is recorded on the company's balance sheet. Investors also form their own opinion of Co Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Co Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Co Diagnostics' market value can be influenced by many factors that don't directly affect Co Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Co Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine Co Diagnostics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Co Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.